aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
BlackThorn Therapeutics is a biopharmaceutical company focused on developing targeted treatments for neurobehavioral disorders. The company aims to address unmet medical needs in the field of mental health through innovative therapies. Based in California, BlackThorn Therapeutics leverages advanced neuroscience and data analytics to create effective solutions for patients.
BlackThorn Therapeutics has made significant strides in the biopharmaceutical industry, contributing to advancements in neurobehavioral disorder treatments. The company's impact is underscored by its commitment to improving mental health outcomes and its innovative approach to drug development.
Operating Status
Acquired
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Treatments
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was BlackThorn Therapeutics founded?
BlackThorn Therapeutics was founded in 2015.
Where is BlackThorn Therapeutics’s headquarters located?
BlackThorn Therapeutics’s headquarters is located in South San Francisco, CA, US.
When was BlackThorn Therapeutics’s last funding round?
BlackThorn Therapeutics’s most recent funding round was for $76M (USD) in June 2019.
How many employees does BlackThorn Therapeutics have?
BlackThorn Therapeutics has 37 employees as of Feb 4, 2024.
How much has BlackThorn Therapeutics raised to-date?
As of July 05, 2023, BlackThorn Therapeutics has raised a total of $138M (USD) since Jun 13, 2019.
Add Comparison
Total Raised to Date
$138M
USD
Last Update Jun 13, 2019
Last Deal Details
$76M
USD
Jun 13, 2019
Series B
Total Employees Over Time
37
As of Feb 2024
BlackThorn Therapeutics Address
329 Oyster Point Blvd
3rd Floor
South San Francisco,
California
94080
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts